THER — Theralink Technologies Share Price
0.000.00%
Last trade - 00:00- $0.62m
- $23.20m
- $0.61m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1251.16% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.18 | 0.51 | 0.57 | 0.61 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
Directors
- Jeffrey Busch CHM (64)
- Mick Ruxin PRE (75)
- Thomas Chilcott CFO (54)
- Yvonne Fors DRC (49)
- Andrew Kucharchuk DRC (41)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 18th, 2005
- Public Since
- April 23rd, 2007
- No. of Shareholders
- 237
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 6,151,499,919
- Address
- 8000 INNOVATION PARK, DR, BATON ROUGE, BATON ROUGE, 70820
- Web
- https://oncbiomune.com/
- Phone
- +1 2255787555
- Auditors
- Salberg & Company, P.A.
Upcoming Events for THER
Similar to THER
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Theralink Technologies share price?
As of Today at 23:43 UTC, shares in Theralink Technologies are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Theralink Technologies share price performed this year?
Shares in Theralink Technologies last closed at $0.00 and the price had moved by -95.24% over the past 365 days. In terms of relative price strength the Theralink Technologies share price has underperformed the S&P500 Index by -96% over the past year.
What are the analyst and broker recommendations for Theralink Technologies?
There is no consensus recommendation for this security.
What is the Theralink Technologies dividend yield?
Theralink Technologies does not currently pay a dividend.
Does Theralink Technologies pay a dividend?
Theralink Technologies does not currently pay a dividend.
When does Theralink Technologies next pay dividends?
Theralink Technologies does not currently pay a dividend.
How do I buy Theralink Technologies shares?
To buy shares in Theralink Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theralink Technologies?
As of the previous close price of $0.00, shares in Theralink Technologies had a market capitalisation of $0.62m.
Where are Theralink Technologies shares listed?
Here are the trading details for Theralink Technologies:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: THER
What kind of share is Theralink Technologies?
Based on an overall assessment of its quality, value and momentum Theralink Technologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theralink Technologies share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Theralink Technologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theralink Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -92.45%.
As of the last closing price of $0.00, shares in Theralink Technologies were trading -90.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theralink Technologies PE Ratio?
The Theralink Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theralink Technologies?
Theralink Technologies' management team is headed by:
- Jeffrey Busch - CHM
- Mick Ruxin - PRE
- Thomas Chilcott - CFO
- Yvonne Fors - DRC
- Andrew Kucharchuk - DRC